U.S. Markets closed

Why Novartis Earnings Provided A Bullish Signal For This Biotech Stock

ALLISON GATLIN
Why Novartis Earnings Provided A Bullish Signal For This Biotech Stock

Incyte's biggest moneymaker, a cancer treatment called Jakafi, could grow by double digits in the first quarter, an analyst said Monday as he maintained a strong-buy rating on Incyte stock.